SAEM GRACE: Anti‐craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence
Authors:
Open Access
- 19 October 2023
- journal article
- review article
- Published by Wiley in Academic Emergency Medicine
- Vol. 31 (5) , 504-514
Abstract
Objectives: Alcohol‐related concerns commonly present to the emergency department (ED), with a subset of individuals experiencing the symptoms of an alcohol use disorder (AUD). As such, examining the efficacy of pharmacological anti‐craving treatment for AUD in the ED is of increasing interest. The objective of this systematic review was to evaluate the direct evidence assessing the efficacy of providing anti‐craving medications for AUD treatment in the ED.Methods: A systematic search was conducted according to the patient‐intervention‐control‐outcome question: (P) adults (≥18 years old) presenting to the ED with an AUD (including suspected AUD); (I) anti‐craving medications (i.e., naltrexone, acamprosate, gabapentin); (C) no prescription or placebo; (O) reduction of repeat ED visits, engagement in addiction services, reductions in heavy drinking days, reductions in any drinking and amount consumed (or abstinence), and in relapse. Two reviewers independently assessed articles for inclusion and conducted risk of bias assessments for included studies.Results: From 143 potentially relevant articles, 6 met inclusion criteria: 3 clinical trials, and 3 case studies. The clinical trials identified evaluated oral versus extended‐release naltrexone, monthly extended‐release naltrexone injections, and disulfiram. Both oral and extended‐release naltrexone resulted in decreased alcohol consumption. Monthly extended‐release naltrexone injections resulted in significant improvements in drinking and quality of life. Although out of scope, the disulfiram studies identified did not result in an improvement in drinking in comparison to no medication.Conclusions: Overall, there are few studies directly examining the efficacy of anti‐craving medications for AUD in the ED, although the limited evidence that exists is supportive of naltrexone pharmacotherapy, particularly extended‐release injection formulation. Additional randomized controlled trials are necessary for substantive direct evidence on anti‐craving medication initiation in the ED.Keywords
Funding Information
- Canada Research Chairs
- Peter Boris Centre for Addictions Research
- Society for Academic Emergency Medicine
This publication has 45 references indexed in Scilit:
- What is the burden of alcohol-related injuries in an inner city emergency department?Emergency Medicine Journal, 2012
- Emergency Department Visits Due to Alcohol Intoxication: Characteristics of Patients and Impact on the Emergency RoomAlcohol and Alcoholism, 2012
- Alcohol use disorders in the emergency ward: choice of the best mode of assessment and identification of at-risk situationsInternational Journal of Emergency Medicine, 2011
- Stigma and Treatment for Alcohol Disorders in the United StatesAmerican Journal of Epidemiology, 2010
- The Mixed Evidence for Brief Intervention in Emergency Departments, Trauma Care Centers, and Inpatient Hospital Settings: What Should We Do?Alcohol, Clinical and Experimental Research, 2010
- Disulfiram in severe alcoholism—an open controlled studyNordic Journal of Psychiatry, 2010
- Effect of motivational interviewing on reduction of alcohol useDrug and Alcohol Dependence, 2010
- Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialtyDrug and Alcohol Dependence, 2009
- A systematic review of emergency care brief alcohol interventions for injury patientsJournal of Substance Abuse Treatment, 2008
- Contingency management for treatment of substance use disorders: a meta‐analysisAddiction, 2006